rosiglitazone has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koh, HC; Lee, EY; Lee, JE; Park, JH; Shin, IC | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
2 other study(ies) available for rosiglitazone and oxidopamine
| Article | Year |
|---|---|
Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Topics: Animals; Basal Ganglia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Injections, Intraperitoneal; Male; Microfilament Proteins; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Substantia Nigra; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |